Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease (Q33503783)

27 July 2017

title

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

27 July 2017

main subject

0 references

1 reference

1 reference

Kirschner BS

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 October 1998

1 reference

27 July 2017

1 reference

27 July 2017

volume

115

1 reference

27 July 2017

1 reference

27 July 2017

page(s)

813-821

1 reference

Longitudinal growth in children and adolescents with inflammatory bowel disease

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Extraintestinal manifestations of inflammatory bowel disease in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Azathioprine in the treatment of children with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Extraintestinal cancers in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Lymphoma in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Risk factors for small bowel cancer in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

6-MP metabolite levels: A potential guide to Crohn's disease therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

Growth and development in chronic inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2898%2970251-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(98)70251-3

1 reference

release_fn67mnhppneapg5grdeeoql3ym

27 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fn67mnhppneapg5grdeeoql3ym

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference